Board Appoints Carlton Turner as Chairman, Robert Schnitzius as Acting President & CEO IRVING, Texas, Dec 11 /PRNewswire-FirstCall/ -- DelSite, Inc.

* First Nasal Powder H5N1 Influenza Vaccine Candidate * Distinct Advantages for Pandemic Preparedness * Phase I Dose-Escalating Study IRVING, Texas, June 26, 2008 (PRIME NEWSWIRE) -- Carrington Laboratories, Inc.

* Safer and More Economical Approach Against a Major Infectious Disease That Causes 500,000 to 600,000 Deaths Worldwide Per Year * Chemical Composition Similar to Marketed Typhoid Vi Polysaccharide Vaccine * Made From cGMP Natural Polysaccharide Material * No Fermentation Required * Cost Substantially Lower Than the Vi Polysaccharide Antigen * Available for Partnering or Licensing IRVING, Texas, June 26, 2008 (PRIME NEWSWIRE) -- DelSite Biotechnologies, Inc., a wholly-owned subsidiary of Carrington Laboratories, Inc.

IRVING, Texas, April 15 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc.

ImmuneRegen® BioSciences, Inc., a wholly owned biotechnology product development and licensing subsidiary of IR BioSciences Holdings, Inc.